Phase II non randomized open clinical evaluation of Siddha medicine Seenthil Chooranam for the management of Madhumegam (Type II Diabetes Mellitus)

Diabetesmellitus is a clinical syndrome characterised by increase in plasma bloodglucose (Hyperglycemia). There are two types of diabetes mellitus ,Type I andType II. Type I Diabetes Mellitus is caused by autoimmune destruction of betacells in the pancreas, resulting in absolute insulin deficiency, whereas TypeI  Diabetes Mellitus is due to insulin deficiency or defective actionof insulin or both.Chronic hyperglycemia is responsible fordiabetes specific microvascular complications affecting the eyes (retinopathy),kidneys (nephropathy) and feet (neuropathy).

Indiais deemed as the world’s capital of Diabetes. In 2021, approximately 537million adults (20-79years of age ) are living with diabetes. The total numberof people living with diabetes is projected to rise to 643 million by 2030 and783 million by 2045.The diabetic population in the country close to hitting thealarming mark of 69.9 million by2030.

Theclassical siddha medicine formulation **“SEENTHIL CHOORANAMâ€**mentionedin **"The Siddha Formulary of India-Part I ".**isindicated for Madhumegam (Diabetes mellitus). Moreover this formulation hasanti-diabetic activity that had been proven scientifically .So the authortries to evaluate its efficacy in the management of Type II DiabetesMellitus)in a non-randomised open clinical trial.